New Delhi: The Bharat Biotech-manufactured Covaxin is overall 77.8 per cent effective against COVID-19, the vaccine-maker said via a statement citing third phase data of clinical trials. The data though is not peer-reviewed.
The vaccine provides “65.2 per cent protection” against the new Delta variant, which is said to be highly infectious, the statement said.
“We are proud to put India on the global map with scientific conviction, competence and commitment. Covaxin scores 10 world-class publications endorsing Innovation, clinical research, data, safety, efficacy. Thank collaborators & Positive BB teamwork enduring a pandemic (sic),” Bharat Biotech co-founder Suchitra Ella said through a late-night tweet.
Bharat Biotech further said in a statement, “Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.”
COVAXIN® Proven SAFE in India’s Largest Efficacy Trial. Final Phase-3 Pre-Print Data Published on https://t.co/JJh9n3aB6V pic.twitter.com/AhnEg56vFN
— BharatBiotech (@BharatBiotech) July 2, 2021
ALSO READ: Covaxin Effective For Delta Variant, Says Top US Health Institute
